114 results about "Nausea" patented technology

The invention relates to the technical field of medical instruments, in particular to emergency clinical emetic equipment which comprises a support, an emetic part arranged on the support and expansion parts symmetrically arranged on the two sides of the emetic part. The retreating assembly is used for driving the support to move so that the expansion pieces and the emetic piece can retreat from the oral cavity of the patient, the support is provided with a first reset piece capable of enabling the emetic piece to be away from the throat and a second reset piece capable of enabling the two expansion pieces to be closed, and the guide rail is provided with a control switch. The vomiting promoting driver drives the vomiting promoting piece to vibrate in the throat of the patient, the vomiting promoting process of the patient is achieved, and when the patient feels strong nausea and is about to have vomiting reaction, the control switch is pressed down in advance; and the emesis promoting piece and the expanding piece quickly restore to original positions under the action of the first resetting piece and the second resetting piece and move out of the oral cavity of the patient through the support, so that the vomiting process is smooth, and the risk that vomit blocks or is inhaled into the airway by mistake is avoided.

This invention provides a novel GABA structure with better efficacy, reduced side effects, and greater safety for clinical use. A This invention relates to receptor agonists, specifically a phenol derivative, its preparation method, and its use in the central nervous system. The phenol derivative provided by this invention offers more and better drug options for inducing or maintaining anesthesia in animals or humans, promoting sedation and hypnosis, and treating and / or preventing anxiety, nausea, vomiting, migraines, seizures, epilepsy, neurodegenerative diseases, and other central nervous system-related disorders.

The present invention discloses a functional solid beverage for resisting altitude sickness and a preparation method thereof. The raw materials of the solid beverage include yak spleen small molecule polypeptide, yak milk small molecule polypeptide, taurine, phosphatidylserine, crystalline fructose and flaxseed; wherein the amino acid sequence of the yak spleen small molecule polypeptide is shown as SEQ ID NO.1, and the amino acid sequence of the yak milk small molecule polypeptide is shown as SEQ ID NO.2. The functional solid beverage of the present invention promotes oxygen carrying and improves the oxygen transport efficiency of red blood cells by reducing the deformation and adhesion of red blood cells caused by plateau exposure, thereby effectively preventing and alleviating altitude sickness such as headache, nausea, fatigue, etc. The product is portable and easy to use, the ingredients are safe and harmless, and the effect has been verified to be significant through experiments. The functional solid beverage of the present invention provides scientific and effective health protection for people entering high-altitude areas, and has broad market prospects and application value.

A traditional Chinese medicine composition for alleviating gastrointestinal toxic side effects caused by chemotherapy, the traditional Chinese medicine composition for daily administration is prepared from the following weight ratio of traditional Chinese medicine formula: Taizishen 20-30g, Fuling 10-15g, Fried Baizhu 10-15g, Zhigancao 5-10g, Jiangbanxia 5-10g, Chenpi 5-15g. The formula can effectively alleviate the gastrointestinal toxic side effects caused by chemotherapy, such as nausea, vomiting, diarrhea, poor appetite, etc.

The present application relates to a kind of traditional Chinese medicine composition for treating pediatric anorexia, the traditional Chinese medicine composition is made of the following weight parts of raw medicinal materials: 7-11 parts of Taizishen, 7-11 parts of Cangzhu, 7-11 parts of Fuling, 7-11 parts of Huoxiang, 7-11 parts of Gegen, 7-11 parts of Qingpi, 6-13 parts of Laiqiezi, 4-8 parts of Lianqiao, 7-11 parts of Sanleng, 7-11 parts of Shanzha.The present application also provides the use of traditional Chinese medicine composition for pediatric anorexia.The present application uses several drugs together, which is integrated with invigorating spleen, transporting spleen and activating spleen, so that the spleen is healthy, the spleen and stomach qi movement is appropriate, and the human body qi movement is adjusted, so that the whole body qi movement is operated, the qi movement is operated, the five internal organs are harmonious, and the whole prescription plays the effect of invigorating spleen and transporting.The total effective rate and the improvement of TCM syndrome score of the traditional Chinese medicine composition of the present application are better than those of the control group, especially in improving the symptoms of anorexia, reduced food intake and other symptoms such as salivation, belching, hiccups, nausea and other symptoms.

Described herein are methods, compositions, products, and processes that utilize bioceramics in traditional agricultural and hydroponic systems. The bioceramics are utilized in powder form, as films, as aerosols, as water based treatment systems, or in solid forms. The methods and bioceramic compositions described here are also used for growing a Cannabis plant. One or more cannabinoids within the plant can be used in therapeutic compositions for the treatment of glaucoma, AIDS wasting syndrome, neuropathic pain, cancer, multiple sclerosis, chemotherapy-induced nausea, and certain seizure disorders.

The invention belongs to the technical field of functional compositions, and discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and the composition comprises the following raw materials in percentage by mass: 13-28% of ginseng, 18-28% of globe artichoke, 10-27% of pueraria peptide, 7-12% of houttuynia cordata, 7-9% of mulberry, 6-9% of gardenia and 10-29% of collagen composite peptide. The composition can reduce alcohol irritation, relieve alcohol absorption and increase the alcohol content; meanwhile, the liver and stomach are protected; meanwhile, alcohol metabolism is rapid, hangover is prevented, headache, dizziness, nausea and other uncomfortable symptoms caused by alcohol are relieved, and the drunkenness degree is relieved. After the medicine is taken for 2-6 months, mild fatty liver and moderate fatty liver can be obviously improved, and severe fatty liver and alcoholic liver can be obviously improved; indexes related to endocrine metabolism, such as blood sugar, blood fat, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, are obviously improved.

The invention discloses an esophagus medicine applying device for a patient in the digestive system department, and relates to the field of medical equipment, the esophagus medicine applying device comprises a medicine applying pipe, an air pipe is fixedly mounted at the bottom of the outer surface of the medicine applying pipe, and a protective air bag is fixedly mounted on one side of the medicine applying pipe and one side of the air pipe; a pressure sensor is installed on the edge portion of one side of the outer surface of the extending pipe, a dosing mechanism is arranged on the outer surface of the medicine applying pipe and used for adjusting different types of dosing modes, the dosing mechanism comprises a dosing connecting part, the dosing connecting part is fixedly installed on the position, close to the upper portion of the protective air bag, of the outer surface of the medicine applying pipe, and a fixing groove is formed in the middle of one side of the outer surface of the dosing connecting part; the closed administration area is formed by inflating the protective air bag, and by matching with real-time monitoring of the pressure sensor, medicine is effectively prevented from flowing back to the stomach and entering the airway by mistake, discomfort such as nausea and sour regurgitation of a patient is reduced, lung injury is avoided, and the administration safety is improved compared with the prior art.

This invention provides a highly thermally stable enteric-coated DHA microcapsule powder, its preparation method, and its applications. The microcapsule powder utilizes a composite wall material system with a specific ratio of raw materials: carbohydrate film-forming materials, protein film-forming materials, hydrophilic colloids, and dietary fiber materials. The resulting dense wall material not only maintains a supportive interface and film-forming structure under hot water reconstitution conditions, exhibiting high-temperature reconstitution stability, but also features an acid-resistant design, ensuring resistance to acid in aqueous solutions and reducing the nausea / gastric reflux after oral administration of the microcapsule powder. This achieves a balance between high-temperature and acid resistance, overcoming the problems of dispersion and nausea / gastric reflux associated with traditional DHA microcapsules. Furthermore, the microcapsules of this invention, through a synergistic system of "lipid-soluble antioxidants + aqueous antioxidants / reducing agents," reduce accelerated oxidation and off-flavor release during high-temperature reconstitution, thereby improving flavor acceptability.

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy or prevention of symptoms of illness and / or for use in therapy or prevention of diseases characterized by said symptoms. The symptoms of illness may be selected from the group of nausea, headache, muscle aches, back pain, shivering, vomiting in a subject wherein said antibody or fragment or scaffold may bind to ADM of amino acids 1 to 52 (SEQ ID NO: 1), or to fragments thereof.

The invention discloses a compound rosa roxburghii tratt preparation for promoting digestion and a preparation method thereof, the rosa roxburghii tratt preparation is prepared by taking rosa roxburghii tratt normal juice and blueberry normal juice as main raw materials and taking lily, pericarpium citri reticulatae, dandelion, agastache rugosus and green tea extract as auxiliary materials, and the compound rosa roxburghii tratt preparation can effectively promote gastric acid secretion, promote gastrointestinal motility and relieve symptoms such as stomach distension, hiccup and nausea. Belongs to the technical field of health-care food. The product is stable in quality, remarkable in effect and safe to take.

Selectively controllable apparatus for insertion into an ear canal, and related methods of use and operation for behavioral control. In one embodiment, the apparatus includes a body configured for insertion into an ear canal. In one variant, the body includes one or more thermal mechanisms which enable selective increase or decrease of temperature of at least portions of the ear canal so as to implement behavioral control of the user, such as to mitigate cravings for food, alcohol, narcotics, or other potentially deleterious substances. In one variant, a mild nausea or pre-nausea condition is created within the user according to a time-temperature profile so as to induce the aforementioned behavioral modification.

The suppression of the gag reflex response, administered through a training device and associated desensitization method(s), without medical intervention, is desirable for many people who suffer from gag reflex response issues. An oral acclimation training device comprise various thickness(es) and length(s) and may have components to prevent swallowing or choking of the device by the user. Further, the device may be part of a kit having multiple training objects with specific attributes (e.g. thickness, depth, shape, finish, texture) that are designed for a specific stage in the training sequence and tailored for the user's inherent gag reflex sensitivity. Training objects are designed to provide optimal stimulus range to cause desensitization but not cause severe gagging or vomiting. The gag suppression stemming from this device is long-term, meaning that it may last for many weeks or months, depending on the individual. This duration may be extended indefinitely by occasional re-training or similar conditioning.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng / mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.

The present invention relates to a preparation which can inhibit the initial release of a specific PRS inhibitor and has an effect of preventing nausea or vomiting side effects that occur when an excess amount of an active ingredient is absorbed at the initial stage.

The present invention relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has the effects of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis and reducing triglyceride levels.

Methods and systems are provided for taking physiological marker measurements for a patient suffering from an eating disorder (e.g., anorexia nervosa, greedy nervosa, violent eating, heterophagia syndrome, ruminant disorder, or truncated food intake). Mathematical analysis of physiological marker measurements is used to create a unique personal prediction model and a unique personal data set for an individual patient, including personal prediction of the entire stage of a disorder (violence, nausea and clearance). The unique personal data set is used to diagnose and monitor specific issues of individual patients associated with eating disorders, determine the severity of the disorders, provide intraday alarms to assist in sustained disorder management or recommend treatment of specific issues of individual patients associated with these eating disorders, or predicts the outcome of a treatment for a particular problem of individual patients associated with these eating disorders.

Disclosed are the use of methods for reducing one or more gastrointestinal side effects in a subject receiving glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy. The methods include administering to a subject receiving GLP-1 RA therapy an amount of homotaurine-like gastrointestinal distress-relieving (HTL-GIDR) composition effective to reduce gastrointestinal side effects of GLP-1 RA therapy, e.g., nausea, vomiting, and constipation. Generally, the HTL-GIDR composition can be homotaurine or a homotaurine analog such as acamprosate calcium and valiltramiprosate (ALZ-801), or a combination thereof. Furthermore, the HTL-GIDR composition may facilitate tolerance during the GLP-1 RA dose escalation phases and enable administration of higher GLP-1 RA doses, thereby enhancing therapeutic outcomes in conditions including diabetes, obesity, and neurodegenerative diseases.

The invention discloses a traditional Chinese medicine composition for treating chemotherapy-related nausea and vomiting, an acupoint patch and a preparation method, and belongs to the technical field of traditional Chinese medicine research. According to a fine-tuning external application formula, acupoint external application is achieved, medicine transdermal absorption is matched with acupoints to stimulate channel and qi combination, and the effect is special and strong; the medication route is changed, oral administration is avoided, and the gastrointestinal burden is relieved. Aromatic traditional Chinese medicines are used for guiding channels, promoting qi circulation, dredging collaterals and promoting transdermal absorption; and the aromatic traditional Chinese medicines enter spleen and stomach channels, enlivene spleen and please stomach, and are helpful for improving gastrointestinal reactions such as nausea and vomiting. The acupoint patch is simple and easy to operate and learn, has a high degree of recognition by the masses, and is easy to popularize in western medicine hospitals and primary hospitals.

The invention discloses a traditional Chinese medicine composition for treating a warm disease clinically belonging to the same disease of defensive qi and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from, by weight, 5-35 parts of bupleurum chinense, 9-50 parts of scutellaria baicalensis, 9-50 parts of artemisia apiacea, 5-35 parts of radix paeoniae rubra, 5-35 parts of moutan bark and 4-26 parts of folia perillae acutae. According to the traditional Chinese medicine composition, the effects of all the medicines are utilized to generate a synergistic effect, and the effects of relieving fever, eliminating evil and detoxifying are achieved together. The traditional Chinese medicine composition is used for treating fever or hyperpyrexia, slight aversion to wind-cold, headache, sweating, thirst, cough and pharyngalgia caused by cold, viral cold and upper respiratory tract infection febrile disease defensive qi, and can be accompanied by nausea, vomiting, neck stiffness, rash appearance, red eye swelling and pain and the like, so that the febrile disease is effectively treated.

To provide polypeptide-containing pharmaceutical compositions.SOLUTION: The invention relates to a pharmaceutical composition comprising a polypeptide, more specifically, a pharmaceutical composition for preventing or treating obesity, diabetes or non-alcoholic fatty liver disease. Th pharmaceutical composition is safe without any side effects such as nausea or vomiting with effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides. The invention relates to a polypeptide-containing pharmaceutical composition, medical use of the polypeptide-containing pharmaceutical composition, for example, use in treatment or prevention of obesity, diabetes or non-alcoholic fatty liver disease.SELECTED DRAWING: None

The invention relates to the field of gastrointestinal surgical nursing, and discloses a gastrointestinal fluid decompression device for gastrointestinal surgical nursing, which comprises a tank body, a negative pressure bottle body is arranged in the tank body, a pressure supplementing assembly is arranged on one side of the tank body, and a partition assembly is arranged above the pressure supplementing assembly. Through the deformation linkage design of the negative-pressure self-adaptive pressure supplementing assembly and the elastic negative-pressure bottle, real-time monitoring and dynamic compensation of the negative pressure in the negative-pressure bottle are achieved, the pressure supplementing strength can be automatically adjusted according to the springback unfolding degree of the negative-pressure bottle, the problems that the negative pressure of a traditional negative-pressure bottle is continuously attenuated, and pressure fluctuation is large are fundamentally solved, and the service life of the negative-pressure bottle is prolonged. And the whole gastrointestinal drainage process is kept in a stable, uniform and effective negative pressure state. The stable drainage pressure can avoid stimulation to gastrointestinal tracts of patients caused by sudden strong and weak suction, uncomfortable symptoms such as abdominal distension, nausea and reflux are remarkably reduced, drainage sufficiency of gastrointestinal fluid is improved, hydrops retention and related complication risks are reduced, and safer and more comfortable decompression guarantee is provided for postoperative recovery of the patients.

The invention provides a nicotine osmotic pump tablet and a preparation method thereof, the nicotine osmotic pump tablet is suitable for the oral cavity, the nicotine osmotic pump tablet comprises a tablet core, the tablet core comprises a drug-containing layer and a boosting layer, the drug-containing layer contains nicotine, and the ratio of the viscosity of the drug-containing layer to the viscosity of the boosting layer is 1: 1.5-1: 2; the tablet core is coated with the semi-permeable membrane; and the release hole can release nicotine after the semipermeable membrane permeates into the liquid. By adopting the nicotine osmotic pump tablet, nicotine is released at an approximately constant rate, the problems that oral mucosa and even stomach are stimulated to cause nausea and the like due to too fast release of nicotine are avoided, and meanwhile, sticky feeling or foreign body sensation is avoided during oral administration.

The present invention relates to a pharmaceutical composition including a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea, and has effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides.

The invention relates to the field of traditional Chinese medicine formulas, and particularly discloses a traditional Chinese medicine composition for treating stomach illness and a preparation method thereof, and each dose of the traditional Chinese medicine composition is prepared from the following components by mass: 30-50 g of rhizoma bletillae, 30 g of radix cynanchi bungei, 20-30 g of cuttle bone, 20-30 g of pseudo-ginseng, 20 g of rhizoma corydalis and 20 g of radix aucklandiae. A method for preparing the traditional Chinese medicine composition for treating stomach diseases comprises the following steps: step 1, mixing the rhizoma bletillae, the radix cynanchi bungei, the cuttle bone, the pseudo-ginseng, the rhizoma corydalis and the radix aucklandiae in proportion, and crushing twice by adopting a high-speed crusher; the traditional Chinese medicine prepared by the invention has a good treatment effect on stomachache, such as gastric ulcer, duodenal ulcer, chronic gastritis, gastrorrhagia, stomachache, stomachache, dyspepsia and the like; through the synergistic effect of various traditional Chinese medicines, the traditional Chinese medicine composition can effectively relieve clinical symptoms such as stomachache, stomachache, sour regurgitation, nausea and vomiting, and meanwhile, can promote the repair of gastric mucosa and the healing of ulcer surfaces.

The invention discloses an infrared glazing dryer for digital presswork, and belongs to the field of digital presswork processing. Comprising a bottom plate, the upper surface of the bottom plate is fixedly connected with a drying box, the left side of the interior of the drying box is provided with a through feeding port, the right side of the interior of the drying box is provided with a through discharging port, and two infrared lamps are symmetrically arranged on the upper portion of the interior of the drying box; solvent waste gas volatilized in the drying process is captured in real time through a negative pressure system composed of an air exhaust box and an air exhaust nozzle, harmful substances in the waste gas are effectively removed in cooperation with adsorption of an activated carbon net and filtration of a filter net, discomfort such as headache and nausea caused by suction of workers is avoided, and the risk of respiratory mucosa injury and liver and kidney dysfunction is reduced; meanwhile, the design that the drawing plate is matched with the handle is adopted, the activated carbon net can be rapidly replaced, the net body stability is ensured through the supporting plate, maintenance does not need tools, and time and labor are saved.

A signal generator is provided that is configured to generate a signal adapted to be delivered to the brain of a subject to alleviate nausea in the subject. The stimulation signal is defined by a waveform having a frequency and a phase. The stimulation signal is characterized by one or more instantaneous disruptions of the phase of the waveform. A system (100) for alleviating nausea is provided. The system (100) comprises: the signal generator (102) configured to generate the stimulation signal; and one or more electrodes (104, 106a-c) configured to deliver the stimulation signal to the brain of a subject.

The invention relates to the treatment of neurodegenerative diseases such as Parkinson patients with motor complications in need of Continuous Dopaminergic Stimulation. According to the invention a kit of pharmaceutical preparations is provided comprising levodopa and an AADC-inhibitor. Levodopa is applied via continuous subcutaneous infusion or by an oral modified release formulation and Continuous Dopaminergic Stimulation is achieved by almost complete inhibition of the peripheral levodopa metabolism. To reach far-going blockage of levodopa metabolism, an AADC-inhibitor (e.g., benserazide, carbidopa) is given orally in a much higher than normal dose and, as an indispensable prerequisite, the AADC-inhibitor has to be applied evenly distributed over the day. e.g., via a Modified Release formulation. In order to prevent levodopa conjugation over the COMT pathway, an oral COMT-inhibitor (e.g., opicapone) is also added. In addition, a drug-drug-interaction between the AADC-inhibitor and opicapone further increasing the activity of the former is likely to occur. The resulting effective inhibition of peripheral levodopa metabolism allows a marked reduction of the necessary (equivalent) levodopa (or prodrug) doses to 300-600 mg / day, which is, however, sufficient to reach high levodopa plasma levels of 1500 to 3000 ng / ml. The low daily levodopa dose is infused subcutaneously via minipump and is well-tolerated at the infusion site. Alternatively, the low daily levodopa dose is provided as an oral modified release formulation. The high steady-state levodopa plasma levels reached, allow effective Continuous Dopaminergic Stimulation-therapy for Parkinson's disease patients of any degree of severity. As additional benefit, the largely complete AADC-inhibition prevents the peripheral generation of dopamine and the cumbersome dopaminergic adverse effects (e.g., nausea, cardiovascular and gastro-intestinal adverse effects) are prevented.